BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 31443351)

  • 1. Disulfiram Overcomes Cisplatin Resistance in Human Embryonal Carcinoma Cells.
    Schmidtova S; Kalavska K; Gercakova K; Cierna Z; Miklikova S; Smolkova B; Buocikova V; Miskovska V; Durinikova E; Burikova M; Chovanec M; Matuskova M; Mego M; Kucerova L
    Cancers (Basel); 2019 Aug; 11(9):. PubMed ID: 31443351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Napabucasin overcomes cisplatin resistance in ovarian germ cell tumor-derived cell line by inhibiting cancer stemness.
    Schmidtova S; Dorssers LCJ; Kalavska K; Gillis AJM; Oosterhuis JW; Stoop H; Miklikova S; Kozovska Z; Burikova M; Gercakova K; Durinikova E; Chovanec M; Mego M; Kucerova L; Looijenga LHJ
    Cancer Cell Int; 2020; 20():364. PubMed ID: 32774158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting of Deregulated Wnt/β-Catenin Signaling by PRI-724 and LGK974 Inhibitors in Germ Cell Tumor Cell Lines.
    Schmidtova S; Kalavska K; Liskova V; Plava J; Miklikova S; Kucerova L; Matuskova M; Rojikova L; Cierna Z; Rogozea A; Konig H; Albany C; Mego M; Chovanec M
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33923996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of the PARP inhibitor veliparib on germ cell tumor cell lines.
    Schmidtova S; Udvorkova N; Cierna Z; Horak S; Kalavska K; Chovanec M; Rojikova L; Vulevova M; Kucerova L; Mego M
    Oncol Lett; 2022 Nov; 24(5):392. PubMed ID: 36276487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Micro-RNA expression in cisplatin resistant germ cell tumor cell lines.
    Port M; Glaesener S; Ruf C; Riecke A; Bokemeyer C; Meineke V; Honecker F; Abend M
    Mol Cancer; 2011 May; 10():52. PubMed ID: 21575166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular Mechanisms of Cisplatin Chemoresistance and Its Circumventing in Testicular Germ Cell Tumors.
    Schmidtova S; Kalavska K; Kucerova L
    Curr Oncol Rep; 2018 Sep; 20(11):88. PubMed ID: 30259297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological inhibition of HDAC6 overcomes cisplatin chemoresistance by targeting cancer stem cells in oral squamous cell carcinoma.
    Tavares MO; Milan TM; Bighetti-Trevisan RL; Leopoldino AM; de Almeida LO
    J Oral Pathol Med; 2022 Jul; 51(6):529-537. PubMed ID: 35678235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of Oct-3/4 expression in embryonal carcinoma cells is associated with induction of cisplatin resistance.
    Mueller T; Mueller LP; Luetzkendorf J; Voigt W; Simon H; Schmoll HJ
    Tumour Biol; 2006; 27(2):71-83. PubMed ID: 16557044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression and roles of system L amino acid transporters in human embryonal carcinoma cells.
    Chatsirisupachai K; Kitdumrongthum S; Panvongsa W; Janpipatkul K; Worakitchanon W; Lertjintanakit S; Wongtrakoongate P; Chairoungdua A
    Andrology; 2020 Nov; 8(6):1844-1858. PubMed ID: 32741077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential New Therapeutic Approaches for Cisplatin-Resistant Testicular Germ Cell Tumors.
    Lengert AVH; Pereira LDNB; Cabral ERM; Gomes INF; Jesus LM; Gonçalves MFS; Rocha AOD; Tassinari TA; Silva LSD; Laus AC; Vidal DO; Pinto MT; Reis RM; Lopes LF
    Front Biosci (Landmark Ed); 2022 Aug; 27(8):245. PubMed ID: 36042160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced proficiency in homologous recombination underlies the high sensitivity of embryonal carcinoma testicular germ cell tumors to Cisplatin and poly (adp-ribose) polymerase inhibition.
    Cavallo F; Graziani G; Antinozzi C; Feldman DR; Houldsworth J; Bosl GJ; Chaganti RS; Moynahan ME; Jasin M; Barchi M
    PLoS One; 2012; 7(12):e51563. PubMed ID: 23251575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relative activity of cisplatin, oxaliplatin and satraplatin in testicular germ cell tumour sensitive and resistant cell lines.
    Perry J; Powles T; Shamash J; Veerupillai A; McGrowder E; Noel E; Lu YJ; Oliver T; Joel S
    Cancer Chemother Pharmacol; 2009 Oct; 64(5):925-33. PubMed ID: 19263053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. VEGF-C inhibition reverses resistance of bladder cancer cells to cisplatin via upregulating maspin.
    Zhu H; Yun F; Shi X; Wang D
    Mol Med Rep; 2015 Aug; 12(2):3163-9. PubMed ID: 25936422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ALDH1A3 upregulation and spontaneous metastasis formation is associated with acquired chemoresistance in colorectal cancer cells.
    Durinikova E; Kozovska Z; Poturnajova M; Plava J; Cierna Z; Babelova A; Bohovic R; Schmidtova S; Tomas M; Kucerova L; Matuskova M
    BMC Cancer; 2018 Aug; 18(1):848. PubMed ID: 30143021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrated Microarray-Based Data Analysis of miRNA Expression Profiles: Identification of Novel Biomarkers of Cisplatin-Resistance in Testicular Germ Cell Tumours.
    Roška J; Lobo J; Ivovič D; Wachsmannová L; Mueller T; Henrique R; Jerónimo C; Chovanec M; Jurkovičová D
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Refractory testicular germ cell tumors are highly sensitive to the second generation DNA methylation inhibitor guadecitabine.
    Albany C; Hever-Jardine MP; von Herrmann KM; Yim CY; Tam J; Warzecha JM; Shin L; Bock SE; Curran BS; Chaudhry AS; Kim F; Sandusky GE; Taverna P; Freemantle SJ; Christensen BC; Einhorn LH; Spinella MJ
    Oncotarget; 2017 Jan; 8(2):2949-2959. PubMed ID: 27936464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel sequential therapy with metformin enhances the effects of cisplatin in testicular germ cell tumours via YAP1 signalling.
    He K; Li Z; Ye K; Zhou Y; Yan M; Qi H; Hu H; Dai Y; Tang Y
    Cancer Cell Int; 2022 Mar; 22(1):113. PubMed ID: 35264157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer stem cell mediated acquired chemoresistance in head and neck cancer can be abrogated by aldehyde dehydrogenase 1 A1 inhibition.
    Kulsum S; Sudheendra HV; Pandian R; Ravindra DR; Siddappa G; R N; Chevour P; Ramachandran B; Sagar M; Jayaprakash A; Mehta A; Kekatpure V; Hedne N; Kuriakose MA; Suresh A
    Mol Carcinog; 2017 Feb; 56(2):694-711. PubMed ID: 27380877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of Disulfiram and Cisplatin in Refractory Germ Cell Tumors. The GCT-SK-006 phase II trial.
    Mego M; Svetlovska D; Angelis V D; Kalavska K; Lesko P; Makovník M; Obertova J; Orszaghova Z; Palacka P; Rečková M; Rejlekova K; Z SM; Mardiak J; Chovanec M
    Invest New Drugs; 2022 Oct; 40(5):1080-1086. PubMed ID: 35763178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disulfiram modulates ROS accumulation and overcomes synergistically cisplatin resistance in breast cancer cell lines.
    Yang Z; Guo F; Albers AE; Sehouli J; Kaufmann AM
    Biomed Pharmacother; 2019 May; 113():108727. PubMed ID: 30870721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.